Background Although muscle loss is thought to be a prognostic factor in chronic obstructive pulmonary disease (COPD) 
Introduction

Chronic obstructive pulmonary disease (COPD) is characterized by not only airflow limitation but also some extrapulmonary comorbidities (1). In particular, skeletal muscle weakness and atrophy are frequently observed in patients with COPD (2); skeletal muscle weakness is associated with a reduced fat-free mass (FFM) of the extremities but not with airflow limitation (3). The pathogenesis of muscle wasting in patients with COPD has attracted considerable research interest. A reduction of physical activity may be responsible for deconditioning, in which metabolic causes have been examined in detail
. Anabolic/catabolic disturbance in COPD leads to a shift toward catabolism, which possibly induces the development of peripheral muscle-wasting (5) ; selective type-IIX and IIA/ IIX atrophy accompanies an increase in fibrosis and fat cell replacement (6, 7) , and skeletal muscle apoptosis increases in COPD (8) . However, it is not known whether these changes are specific to COPD, since similar muscle-wasting is associated with inflammatory changes in patients with chronic diseases such as those on long-term hemodialysis (9) or with chronic heart disease (10) . The relationship be-tween skeletal muscle dysfunction, aging and immobility is not clear (11, 12) . Immobilization in advanced aging (13) , severe dyspnea in COPD (14) or combined with chronic disease and immobilization (15) may result in muscle-wasting. This muscle-wasting is associated with a poor prognosis, and if FFM depletion can be reversed, the prognosis also improves (16) .
Despite the fact that the fat mass (FM) cannot be used to predict COPD survival, FM could be associated with comorbidities in COPD patients, since a recent review (17) showed that COPD has extra-pulmonary effects, including an increased risk of cardiovascular disease, osteoporosis, and several neurologic defects. FM is reported to be an independent risk factor for myocardial infarction (18) and to be associated with systemic inflammation (19 (21) .
Materials and Methods
Parameters
Muscle strength
Handgrip strength was measured with a hand dynamometer (GRIP-A; Takei Scientific Instruments Co., Niigata, Japan). Three measurements were made using each hand with the arm unsupported, and the maximal grip strength for each hand was used.
Exercise capacity
The 6 MWT was conducted according to ATS standards (25) . During the 6 MWT, oximetry was performed every 10 seconds with a pulse oximeter (Pulseox; Teijin Co., Tokyo Japan).
Pulmonary function testing
Pulmonary function parameters, including postbronchodilator FEV1, carbon monoxide diffusing capacity (DLCO), vital capacity (VC), and forced vital capacity (FVC), were measured according to the American Thoracic
Society guidelines (26) (27) .
Quantitative analysis on CT
We calculated the extent of the low-attenuation area (% LAA) by HRCT scan, according to Nakano et al, with a slight modification (20 
Results
Characteristics of the subjects
A total of 112 male smokers (27 current T a b l e 1 . Ch a r a c t e r i s t i c s o f t h e S u b j e c t T a b l e 2 . Co r r e l a t i o n s b e t we e n F F MI o r F MI a n d Cl i n i c a l Va r i a b l e s b Table 2 ) were used as dependent variables for stepwise analysis.
T a b l e 3 . Re s u l t s o f Mu l t i v a r i a t e L i n e a r Re g r e s s i o n An a l y s i s o f F F MI
2. Dependent variables with p-values of less than 0.05 are shown.
See Table 1 for abbreviations.
ported that skeletal muscle strength could be a predictor of all-cause mortality in healthy men (29 Table 2) were used as dependent variables for stepwise analysis.
F i g u r e 1 . S c a t t e r p l o t s o f t h e F F MI a n d F MI a g a i n s t %L AA i n 1 1 2 ma l e COP D p a t i e n t s ( P a n e l s A a n d B , r e s p e c t i v e l y ) . Re g r e s s i o n l i n e s a r e a l s o s h o wn . S e e T a b l e 1 f o r a b b r e v i a t i o n s .
T a b l e 4 . Re s u l t s o f Mu l t i v a r i a t e L i n e a r Re g r e s s i o n An a l y s i s o f F MI
Regression coefficient
See Table 1 (35) .
Fourth, it is of interest to note that the data of both packyears and adiponectin were also associated with FM in COPD ( Table 2) . It has been reported that smoking is related to the body FM in a general population sample (36) , which is consistent with the present results. The role of adiponectin has been studied in various lung diseases, including bronchial asthma (37) ; however, to the best of our knowledge, only a few previous reports have investigated the role of adiponectin in COPD (38) . Shore suggested that adiponectin has an anti-inflammatory effect in asthma (37) ; if this is also true in COPD, there is a possibility that adiponectin has a protective effect against chronic inflammation in COPD in cases of a low FM, which is consistent with a recent report (38) . FM alone is reported as an independent risk factor of myocardial infarction (18) , which is also known as one of the comorbidities of COPD (1) 
